Moderna stock falls after leaked cancer vaccine data
Moderna stock falls up to 25% after a partial leak of data on its personalized cancer vaccine with Merck, despite full results showing meaningful benefits.
Moderna stock falls up to 25% after a partial leak of data on its personalized cancer vaccine with Merck, despite full results showing meaningful benefits.